Donald Steen, chairman of the board of AmeriPath, has been named chief executive officer for the Riviera Beach, Fla., company, which manages and operates pathology laboratories and provides molecular diagnostics services, AmeriPath said in a statement last week. Steen was named chairman of the company on March 22, replacing Jim New, who was chairman and CEO before retiring Feb. 1, according to SEC documents.
Bernard Kasten joins SIGA Technologies of New York as chief executive officer. Previously Kasten was vice president of medical affairs of the MedPlus subsidiary of Quest Diagnostics. Kasten, a member of SIGA’s board of directors since May 2003, is a graduate of the Ohio State University College of Medicine.
Anud Aunstrup joins Nuevolution of Copenhagen, Denmark, as chief executive officer, replacing Zaed Subhan, who resigned for personal reasons, the company said last week. Aunstrup previously led Novo Nordisk’s biotechnology division with global responsibility for R&D. He was also president of Novo Nordisk China.
Holly Britt Anderson and Jessica Eason-Butler have joined Velcura Therapeutics, of Ann Arbor, Mich. Anderson, the laboratory administrator, was manager of the central laboratory for reproductive sciences program at the University of Michigan, and was also chief operating officer for Innovative Software Technologies in Ann Arbor. Eason-Butler is a staff scientist at Velcura studying bone cell development. She earned an MS in animal science at Michigan State University.
Thomas Stamey has been appointed to the Scientific Advisory Board of Health Discovery, in Savannah, Georgia. Stamey is the chairman of the department of urology at Stanford University School of Medicine and a leading researcher on prostate cancer, looking for alternatives to PSA. He earned his MD from Johns Hopkins University School of Medicine and was an associate professor of urology there before going to Stanford to found the urology department in 1964.